Literature DB >> 16479521

Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality.

Jean H Humphrey1, Peter J Iliff, Edmore T Marinda, Kuda Mutasa, Lawrence H Moulton, Henry Chidawanyika, Brian J Ward, Kusum J Nathoo, Lucie C Malaba, Lynn S Zijenah, Partson Zvandasara, Robert Ntozini, Faith Mzengeza, Agnes I Mahomva, Andrea J Ruff, Michael T Mbizvo, Clare D Zunguza.   

Abstract

BACKGROUND: Low maternal serum retinol level is a risk factor for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV). Multiple-large-dose vitamin A supplementation of HIV-positive children reduces mortality. The World Health Organization recommends single-large-dose vitamin A supplementation for postpartum women in areas of prevalent vitamin A deficiency; neonatal dosing is under consideration. We investigated the effect that single-large-dose maternal/neonatal vitamin A supplementation has on MTCT, HIV-free survival, and mortality in HIV-exposed infants.
METHODS: A total of 14,110 mother-infant pairs were enrolled < or =96 h after delivery, and both mother and infant, mother only, infant only, or neither received vitamin A supplementation in a randomized, placebo-controlled trial with a 2 x 2 factorial design. All but 4 mothers initiated breast-feeding. A total of 4495 infants born to HIV-positive women were included in the present analysis.
RESULTS: Neither maternal nor neonatal vitamin A supplementation significantly affected postnatal MTCT or overall mortality between baseline and 24 months. However, the timing of infant HIV infection modified the effect that supplementation had on mortality. Vitamin A supplementation had no effect in infants who were polymerase chain reaction (PCR) positive [corrected] for HIV at baseline. In infants who were PCR negative at baseline and PCR positive at 6 weeks, neonatal supplementation reduced mortality by 28% (P=.01), but maternal supplementation had no effect. In infants who were PCR negative at 6 weeks, all 3 vitamin A regimens were associated with ~2-fold higher mortality (P< or =.05).
CONCLUSIONS: Targeted vitamin A supplementation of HIV-positive children prolongs their survival. However, postpartum maternal and neonatal vitamin A supplementation may hasten progression to death in breast-fed children who are PCR negative at 6 weeks. These findings raise concern about universal maternal or neonatal vitamin A supplementation in HIV-endemic areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479521     DOI: 10.1086/500366

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  70 in total

1.  Postpartum plasma CD4 change in HIV-positive women: implications for timing of HAART initiation.

Authors:  Ai Koyanagi; Andrea J Ruff; Lawrence H Moulton; Robert Ntozini; Kuda Mutasa; Peter Iliff; Jean H Humphrey
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

Review 2.  Role of nutrients in the development of neonatal immune response.

Authors:  Susanna Cunningham-Rundles; Hong Lin; Deborah Ho-Lin; Ann Dnistrian; Barrie R Cassileth; Jeffrey M Perlman
Journal:  Nutr Rev       Date:  2009-11       Impact factor: 7.110

3.  Sex differences in the effects of maternal vitamin supplements on mortality and morbidity among children born to HIV-infected women in Tanzania.

Authors:  Kosuke Kawai; Gernard Msamanga; Karim Manji; Eduardo Villamor; Ronald J Bosch; Ellen Hertzmark; Wafaie W Fawzi
Journal:  Br J Nutr       Date:  2010-03-09       Impact factor: 3.718

Review 4.  Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE).

Authors:  Daniel J Raiten; Fayrouz A Sakr Ashour; A Catharine Ross; Simin N Meydani; Harry D Dawson; Charles B Stephensen; Bernard J Brabin; Parminder S Suchdev; Ben van Ommen
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

Review 5.  New challenges in studying nutrition-disease interactions in the developing world.

Authors:  Andrew M Prentice; M Eric Gershwin; Ulrich E Schaible; Gerald T Keusch; Cesar G Victora; Jeffrey I Gordon
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.

Authors:  Haruka Kamiyama; Katsura Kakoki; Sayuri Shigematsu; Mai Izumida; Yuka Yashima; Yuetsu Tanaka; Hideki Hayashi; Toshifumi Matsuyama; Hironori Sato; Naoki Yamamoto; Tetsuro Sano; Yoshihiro Shidoji; Yoshinao Kubo
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

7.  Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial.

Authors:  Christine Stabell Benn; Ane Baerent Fisker; Bitiguida Mutna Napirna; Adam Roth; Birgitte Rode Diness; Karen Rokkedal Lausch; Henrik Ravn; Maria Yazdanbakhsh; Amabelia Rodrigues; Hilton Whittle; Peter Aaby
Journal:  BMJ       Date:  2010-03-09

8.  A randomized trial to determine the optimal dosage of multivitamin supplements to reduce adverse pregnancy outcomes among HIV-infected women in Tanzania.

Authors:  Kosuke Kawai; Roland Kupka; Ferdinand Mugusi; Said Aboud; James Okuma; Eduardo Villamor; Donna Spiegelman; Wafaie W Fawzi
Journal:  Am J Clin Nutr       Date:  2009-11-25       Impact factor: 7.045

9.  Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: a mathematical approach.

Authors:  Rolina D van Gaalen; Lindi M Wahl
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

10.  Functional genetic variants in DC-SIGNR are associated with mother-to-child transmission of HIV-1.

Authors:  Geneviève Boily-Larouche; Anne-Laure Iscache; Lynn S Zijenah; Jean H Humphrey; Andrew J Mouland; Brian J Ward; Michel Roger
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.